Dhruv Kam Sethi

Title: Dhruv Kam Sethi: Innovator in Cancer Therapeutics

Introduction

Dhruv Kam Sethi is a prominent inventor based in Belmont, MA (US). He has made significant contributions to the field of cancer therapeutics through his innovative work on multi-specific binding proteins. His research focuses on developing novel treatments for cancers expressing CD33, a critical target in oncology.

Latest Patents

Dhruv Kam Sethi holds a patent for "Multi-specific binding proteins that bind CD33, NKG2D, and CD16, and methods of use." This patent describes multi-specific binding proteins that target and kill human cancer cells expressing CD33 (Siglec-3). The invention highlights the potency of these proteins in comparison to traditional anti-CD33 monoclonal antibodies, showcasing their ability to achieve maximum lysis of target cells. The multi-specific binding proteins consist of a CD33-binding domain, an NKG2D-binding domain, and a CD16-binding domain, making them a promising avenue for cancer treatment.

Career Highlights

Dhruv Kam Sethi is currently associated with Dragonfly Therapeutics, Inc., where he continues to advance his research in cancer therapeutics. His work has garnered attention for its potential to improve treatment outcomes for patients with CD33 expressing cancers.

Collaborations

He collaborates with notable colleagues, including Gregory P Chang and Ann F Cheung, who contribute to the innovative research environment at Dragonfly Therapeutics, Inc.

Conclusion

Dhruv Kam Sethi's contributions to the field of cancer therapeutics through his patented innovations demonstrate his commitment to advancing medical science. His work holds promise for improving treatment options for patients facing challenging cancers.